Skip to main content
    S

    STAAR Surgical Company (STAA)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $26.01
    -0.38 (-1.44%)

    Market Cap: $1.32B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    STAAR Surgical Company (STAA) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    STAAR Surgical Company (STAA) trades at 35.2x trailing earnings and 4.0x sales. Its P/S of 4.0x is below its 5-year median of 5.7x. Its forward P/E is 47.2x. The median P/E across 8 similar companies is 24.6x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 25.4% lower over the next year. Its free cash flow yield is 1.4%.

    MultipleValue
    P/E (trailing)35.2x
    Forward P/E47.2x
    Price to sales4.0x
    Price to book3.5x
    EV/EBITDA92.1x
    Price to FCF73.7x
    EV/FCF66.2x
    PEG0.8
    FCF yield1.4%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 51.8% below 8.3x and its P/B is 66.3% below 10.4x.

    MultipleCurrent5-year median10-year median
    P/S4.0x5.7x8.3x
    P/B3.5x4.3x10.4x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 6 of the 10 year ends shown that have a P/E, its P/E ranged from 30.0x in 2023 to 220.1x in 2020. 2023 was the lowest of those years.

    Year endPriceP/EP/SP/B
    2025$23.09N/A4.8x3.3x
    2024$24.29N/A3.8x3.0x
    2023$31.2130.0x4.7x4.0x
    2022$48.5439.8x8.2x7.1x
    2021$91.30104.9x18.9x17.5x
    2020$79.22220.1x22.5x19.6x
    2019$35.1774.8x10.6x10.3x
    2018$31.91118.2x11.1x11.3x
    2017$15.50N/A7.0x14.9x
    2016$10.85N/A5.3x11.6x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About STAA

    What is STAA's forward P/E ratio?

    STAAR Surgical Company has a forward P/E ratio of 47.2x.

    Is STAA stock overvalued?

    GNG's valuation label for STAA is Undervalued. Its P/E of 35.2x compares with a median of 24.6x across 8 similar companies.

    What is STAA's price to sales ratio?

    STAAR Surgical Company has a price to sales ratio of 4.0x.

    What is STAA's PEG ratio?

    STAAR Surgical Company has a PEG ratio of 0.8.